COMP <GO>
JNJ vs MRK // EV/EBITDA & P/E VALUATION
Johnson & Johnson (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: JNJ 9
— MRK 6
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JNJ VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JNJ | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.90% | 74.80% | -6.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.50% | 20.70% | +4.80 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 18.5x | 15.3x | +3.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.97% | 3.42% | -0.45 | MRK | /fcf-yield <GO> |
| Operating Margin | 34.70% | 34.30% | +0.40 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 28.50% | 28.10% | +0.40 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 6.00% | 1.30% | +4.70 | JNJ | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.59 | 5.19 | +0.40 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.4 | 56.9 | +3.49 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 0.92 | +0.16 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 23.0x | 18.4x | +4.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $662.49B | $361.02B | $301.47B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JNJ REV | MRK REV | JNJ GROSS % | MRK GROSS % | JNJ FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $94.19B | $65.01B | 67.9% | 74.8% | $19.70B | $12.36B |
| FY 2024 | $88.82B | $64.17B | 69.1% | 76.3% | $19.84B | $18.10B |
| FY 2023 | $85.16B | $60.12B | 44.0% | 44.0% | $18.96B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JNJ // BETA 1.08
MRK // BETA 0.92